Annual FCF
-$109.90 M
+$36.30 M+24.83%
31 December 2023
Summary:
Tonix Pharmaceuticals Holding annual free cash flow is currently -$109.90 million, with the most recent change of +$36.30 million (+24.83%) on 31 December 2023. During the last 3 years, it has fallen by -$52.77 million (-92.36%). TNXP annual FCF is now -465569.49% below its all-time high of -$23.60 thousand, reached on 31 December 2008.TNXP Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$18.81 M
-$8.89 M-89.64%
30 September 2024
Summary:
Tonix Pharmaceuticals Holding quarterly free cash flow is currently -$18.81 million, with the most recent change of -$8.89 million (-89.64%) on 30 September 2024. Over the past year, it has increased by +$6.39 million (+25.35%). TNXP quarterly FCF is now -940400.00% below its all-time high of -$2000.00, reached on 30 June 2010.TNXP Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$69.19 M
+$6.39 M+8.45%
30 September 2024
Summary:
Tonix Pharmaceuticals Holding TTM free cash flow is currently -$69.19 million, with the most recent change of +$6.39 million (+8.45%) on 30 September 2024. Over the past year, it has increased by +$44.90 million (+39.36%). TNXP TTM FCF is now -768677.78% below its all-time high of -$9000.00, reached on 31 March 2008.TNXP TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TNXP Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +24.8% | +25.4% | +39.4% |
| 3 y3 years | -92.4% | +9.1% | +14.8% |
| 5 y5 years | -358.4% | -183.0% | -157.8% |
TNXP Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -92.4% | +24.8% | -89.6% | +63.3% | at high | +58.6% |
| 5 y | 5 years | -358.4% | +24.8% | -183.0% | +63.3% | -159.1% | +58.6% |
| alltime | all time | <-9999.0% | +24.8% | <-9999.0% | +63.3% | <-9999.0% | +58.6% |
Tonix Pharmaceuticals Holding Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$18.81 M(+89.6%) | -$69.19 M(-8.5%) |
| June 2024 | - | -$9.92 M(-43.9%) | -$75.58 M(-16.8%) |
| Mar 2024 | - | -$17.68 M(-22.4%) | -$90.87 M(-17.3%) |
| Dec 2023 | -$109.90 M(-24.8%) | -$22.78 M(-9.6%) | -$109.90 M(-3.7%) |
| Sept 2023 | - | -$25.20 M(-0.1%) | -$114.09 M(-5.9%) |
| June 2023 | - | -$25.21 M(-31.3%) | -$121.25 M(-7.9%) |
| Mar 2023 | - | -$36.71 M(+36.1%) | -$131.65 M(-10.0%) |
| Dec 2022 | -$146.20 M(+31.9%) | -$26.97 M(-16.6%) | -$146.20 M(-12.6%) |
| Sept 2022 | - | -$32.35 M(-9.1%) | -$167.29 M(+7.5%) |
| June 2022 | - | -$35.61 M(-30.5%) | -$155.64 M(+10.7%) |
| Mar 2022 | - | -$51.26 M(+6.6%) | -$140.56 M(+26.8%) |
| Dec 2021 | -$110.86 M(+94.1%) | -$48.07 M(+132.2%) | -$110.86 M(+36.5%) |
| Sept 2021 | - | -$20.70 M(+0.8%) | -$81.25 M(+1.7%) |
| June 2021 | - | -$20.54 M(-4.8%) | -$79.85 M(+15.1%) |
| Mar 2021 | - | -$21.56 M(+16.9%) | -$69.37 M(+21.4%) |
| Dec 2020 | -$57.13 M(+114.0%) | -$18.45 M(-4.4%) | -$57.13 M(+25.9%) |
| Sept 2020 | - | -$19.30 M(+92.0%) | -$45.37 M(+38.7%) |
| June 2020 | - | -$10.05 M(+7.8%) | -$32.72 M(+19.5%) |
| Mar 2020 | - | -$9.33 M(+39.4%) | -$27.38 M(+2.5%) |
| Dec 2019 | -$26.70 M(+11.4%) | -$6.69 M(+0.6%) | -$26.70 M(-0.5%) |
| Sept 2019 | - | -$6.65 M(+40.9%) | -$26.84 M(+7.0%) |
| June 2019 | - | -$4.72 M(-45.5%) | -$25.08 M(-3.0%) |
| Mar 2019 | - | -$8.65 M(+26.8%) | -$25.85 M(+7.8%) |
| Dec 2018 | -$23.98 M(+25.3%) | -$6.82 M(+39.4%) | -$23.98 M(+8.6%) |
| Sept 2018 | - | -$4.89 M(-10.8%) | -$22.08 M(-0.7%) |
| June 2018 | - | -$5.49 M(-19.0%) | -$22.24 M(+5.3%) |
| Mar 2018 | - | -$6.77 M(+37.4%) | -$21.11 M(+10.3%) |
| Dec 2017 | -$19.13 M(-48.8%) | -$4.93 M(-2.3%) | -$19.13 M(-2.6%) |
| Sept 2017 | - | -$5.05 M(+15.7%) | -$19.64 M(-14.6%) |
| June 2017 | - | -$4.36 M(-9.0%) | -$22.99 M(-13.6%) |
| Mar 2017 | - | -$4.79 M(-11.9%) | -$26.62 M(-28.8%) |
| Dec 2016 | -$37.38 M | -$5.44 M(-35.2%) | -$37.38 M(-14.9%) |
| Sept 2016 | - | -$8.39 M(+5.0%) | -$43.90 M(-8.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2016 | - | -$8.00 M(-48.6%) | -$47.87 M(-2.8%) |
| Mar 2016 | - | -$15.55 M(+30.0%) | -$49.26 M(+15.2%) |
| Dec 2015 | -$42.77 M(+84.7%) | -$11.96 M(-3.2%) | -$42.77 M(+9.2%) |
| Sept 2015 | - | -$12.36 M(+31.6%) | -$39.15 M(+23.1%) |
| June 2015 | - | -$9.39 M(+3.7%) | -$31.80 M(+13.0%) |
| Mar 2015 | - | -$9.05 M(+8.5%) | -$28.15 M(+21.5%) |
| Dec 2014 | -$23.16 M(+171.4%) | -$8.34 M(+66.3%) | -$23.16 M(+26.2%) |
| Sept 2014 | - | -$5.02 M(-12.5%) | -$18.35 M(+13.2%) |
| June 2014 | - | -$5.73 M(+41.0%) | -$16.21 M(+44.2%) |
| Mar 2014 | - | -$4.07 M(+14.9%) | -$11.24 M(+31.7%) |
| Dec 2013 | -$8.53 M(+48.4%) | -$3.54 M(+23.2%) | -$8.53 M(+31.3%) |
| Sept 2013 | - | -$2.87 M(+277.3%) | -$6.50 M(+31.8%) |
| June 2013 | - | -$761.00 K(-44.1%) | -$4.93 M(-7.5%) |
| Mar 2013 | - | -$1.36 M(-9.5%) | -$5.33 M(-7.2%) |
| Dec 2012 | -$5.75 M(+117.7%) | -$1.51 M(+15.6%) | -$5.75 M(+0.7%) |
| Sept 2012 | - | -$1.30 M(+11.9%) | -$5.71 M(+15.0%) |
| June 2012 | - | -$1.16 M(-34.5%) | -$4.97 M(+23.1%) |
| Mar 2012 | - | -$1.78 M(+21.2%) | -$4.03 M(+52.8%) |
| Dec 2011 | -$2.64 M(+108.3%) | -$1.47 M(+162.6%) | -$2.64 M(+10.2%) |
| Sept 2011 | - | -$558.50 K(+141.4%) | -$2.40 M(+30.2%) |
| June 2011 | - | -$231.40 K(-39.7%) | -$1.84 M(+14.2%) |
| Mar 2011 | - | -$383.70 K(-68.6%) | -$1.61 M(+30.6%) |
| Dec 2010 | -$1.27 M(+4443.4%) | -$1.22 M(>+9900.0%) | -$1.23 M(+9535.2%) |
| Sept 2010 | - | -$2000.00(0.0%) | -$12.80 K(-4.5%) |
| June 2010 | - | -$2000.00(-69.2%) | -$13.40 K(-47.0%) |
| Mar 2010 | - | -$6500.00(+182.6%) | -$25.30 K(-9.3%) |
| Dec 2009 | -$27.90 K(+18.2%) | -$2300.00(-11.5%) | -$27.90 K(-8.5%) |
| Sept 2009 | - | -$2600.00(-81.3%) | -$30.50 K(-6.7%) |
| June 2009 | - | -$13.90 K(+52.7%) | -$32.70 K(+39.1%) |
| Mar 2009 | - | -$9100.00(+85.7%) | -$23.50 K(+0.4%) |
| Dec 2008 | -$23.60 K | -$4900.00(+2.1%) | -$23.40 K(+26.5%) |
| Sept 2008 | - | -$4800.00(+2.1%) | -$18.50 K(+35.0%) |
| June 2008 | - | -$4700.00(-47.8%) | -$13.70 K(+52.2%) |
| Mar 2008 | - | -$9000.00 | -$9000.00 |
FAQ
- What is Tonix Pharmaceuticals Holding annual free cash flow?
- What is the all time high annual FCF for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding annual FCF year-on-year change?
- What is Tonix Pharmaceuticals Holding quarterly free cash flow?
- What is the all time high quarterly FCF for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding quarterly FCF year-on-year change?
- What is Tonix Pharmaceuticals Holding TTM free cash flow?
- What is the all time high TTM FCF for Tonix Pharmaceuticals Holding?
- What is Tonix Pharmaceuticals Holding TTM FCF year-on-year change?
What is Tonix Pharmaceuticals Holding annual free cash flow?
The current annual FCF of TNXP is -$109.90 M
What is the all time high annual FCF for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high annual free cash flow is -$23.60 K
What is Tonix Pharmaceuticals Holding annual FCF year-on-year change?
Over the past year, TNXP annual free cash flow has changed by +$36.30 M (+24.83%)
What is Tonix Pharmaceuticals Holding quarterly free cash flow?
The current quarterly FCF of TNXP is -$18.81 M
What is the all time high quarterly FCF for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high quarterly free cash flow is -$2000.00
What is Tonix Pharmaceuticals Holding quarterly FCF year-on-year change?
Over the past year, TNXP quarterly free cash flow has changed by +$6.39 M (+25.35%)
What is Tonix Pharmaceuticals Holding TTM free cash flow?
The current TTM FCF of TNXP is -$69.19 M
What is the all time high TTM FCF for Tonix Pharmaceuticals Holding?
Tonix Pharmaceuticals Holding all-time high TTM free cash flow is -$9000.00
What is Tonix Pharmaceuticals Holding TTM FCF year-on-year change?
Over the past year, TNXP TTM free cash flow has changed by +$44.90 M (+39.36%)